Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Operating Leases (2019 - 2025)

Tg Therapeutics has reported Operating Leases over the past 7 years, most recently at $7.0 million for Q4 2025.

  • Quarterly results put Operating Leases at $7.0 million for Q4 2025, down 13.67% from a year ago — trailing twelve months through Dec 2025 was $7.0 million (down 13.67% YoY), and the annual figure for FY2025 was $7.0 million, down 13.67%.
  • Operating Leases for Q4 2025 was $7.0 million at Tg Therapeutics, down from $7.3 million in the prior quarter.
  • Over the last five years, Operating Leases for TGTX hit a ceiling of $10.6 million in Q3 2022 and a floor of $7.0 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $9.7 million (2023), compared with a mean of $9.2 million.
  • Biggest five-year swings in Operating Leases: grew 5.61% in 2022 and later fell 13.67% in 2025.
  • Tg Therapeutics' Operating Leases stood at $9.8 million in 2021, then grew by 5.05% to $10.3 million in 2022, then decreased by 10.76% to $9.2 million in 2023, then decreased by 11.89% to $8.1 million in 2024, then decreased by 13.67% to $7.0 million in 2025.
  • The last three reported values for Operating Leases were $7.0 million (Q4 2025), $7.3 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.